Cergentis
Menu

TLA for enhanced Apollo X CHO clone screening

14 July 2020News Update

FUJIFILM Diosynth Biotechnologies & Cergentis Application note

 

For a quick and efficient delivery of lifesaving therapies to patients, including recombinant monoclonal antibodies, ensuring speed and high quality are equally important. Quality can be determined by the genomic location and integrity of the transgene sequence within recombinant cell lines.

 

Conventional, often time-consuming technologies for genetic characterization of such cell lines often provide incomplete information and generated results can be difficult to interpret. Targeted Locus Amplification (TLA), a NGS-based technology, is a powerful tool that overcomes these challenges and provides information-rich analysis of transgenes and their integration sites within weeks.

 

Apollo X technology is FUJIFILM Diosynth Biotechnologies’ latest mammalian expression system for fast and high-quality cell line development process. In this latest application note, we describe how FUJIFILM Diosynth Biotechnologies, with the integration of TLA, can support rapid characterization of clonal cell lines during Apollo X cell line development and clone selection. TLA can be applied in various stages of the Apollo X cell line development process.

 

FUJIFILM Diosynth Biotechnologies is a renowned CDMO supporting their customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies.

 

DOWNLOAD APPLICATION NOTE

 

 

 

 

 

 

 

© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.